Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats
Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride g...
Saved in:
Published in | Journal of international medical research Vol. 49; no. 3; p. 300060519841165 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
London, England
SAGE Publications
01.03.2021
Sage Publications Ltd SAGE Publishing |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.
Methods
Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls.
Results
Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced.
Conclusions
Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats. |
---|---|
AbstractList | Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Results Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Conclusions Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats. Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Results Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Conclusions Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats. To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.OBJECTIVESTo investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls.METHODSFifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls.Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced.RESULTSRelative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced.Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats.CONCLUSIONSAstragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats. To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Fifty diabetic rats were randomly placed into five groups (n = 10 each): the diabetes mellitus (DM) group received intragastric saline, the metformin hydrochloride group received intragastric metformin hydrochloride, and the astragaloside-30, -60, and -120 groups received intragastric astragaloside 30 mg/kg, 60 mg/kg, and 120 mg/kg for 28 days, respectively. Ten non-diabetic rats received intragastric saline as controls. Relative to the DM group, fasting blood glucose, triglyceride, total cholesterol, serum alanine transaminase, and serum aspartate aminotransferase levels decreased in the astragaloside-60 and astragaloside-120 groups; serum alkaline phosphatase decreased solely in the astragaloside-120 group. Serum superoxide dismutase (SOD), glutathione (GSH-Px), and catalase (CAT) levels were elevated, while maleic dialdehyde (MDA) decreased in the astragaloside-120 group, relative to the DM group. Relative to the DM group, the liver index and liver cell apoptosis rate were reduced, while histopathological changes in liver tissue were ameliorated in the astragaloside groups; moreover, liver tissue SOD, GSH-Px, and CAT levels were increased, while liver tissue MDA was reduced. Astragaloside IV can lower blood glucose, regulate blood lipids, and protect liver function in diabetic rats. |
Author | Han, Dong |
Author_xml | – sequence: 1 givenname: Dong orcidid: 0000-0002-5945-4731 surname: Han fullname: Han, Dong email: handong6717@163.com organization: Department of Pharmacy, Cangzhou Central Hospital, Cangzhou, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33706619$$D View this record in MEDLINE/PubMed |
BookMark | eNp9ks1rFTEUxYNU7Gt170oCblx0NN-T2QhS_HhQcFPdhkySmeaRN3kmmYrQP74ZX1vtA10F7vmdw-HenICjKU4OgJcYvcW4bd8hihASiONOMowFfwJWmLW0IXV-BFaL3Cz6MTjJeYMQI4KTZ-CY0hYJgbsVuLlMTpetmwr86csV1LkkPeoQs7cOrr_D5OxsnIV9iNHCMcwmZndWx-McdHkQgt95m8-gnizcpVicWbTgr12CwzyZ4uME_QSt170r3sCkS34Ong46ZPfi7j0F3z59vDz_0lx8_bw-_3DRGE5kaQY9yFajbrCCDrgTHcVMSN63xAlJNCISEy0JHwiiHbNd30uNhOHIcuqk6egpWO9zbdQbtUt-q9MvFbVXvwcxjUqnWio41VHiGLJOip4xQ2RviR3Y0EnDuWQtrlnv91m7ud86a-rmkg6PQh8rk79SY7xWEgvBMKoBb-4CUvwxu1zU1mfjQtCTi3NWhCNMhJSMV_T1AbqJc5rqqhaqZS2jklXq1d-NHqrcH7kCYg-YFHNOblDGF71cpBb0QWGklt-kDn9TNaID4332fyzN3pL16P7U_Sd_CwJ316A |
CitedBy_id | crossref_primary_10_1002_ptr_8432 crossref_primary_10_1007_s11356_023_25766_3 crossref_primary_10_3389_fendo_2023_1190827 crossref_primary_10_1016_j_jchromb_2024_124194 crossref_primary_10_3390_ijms241813762 crossref_primary_10_1002_ptr_8229 crossref_primary_10_1097_IM9_0000000000000139 crossref_primary_10_1016_j_heliyon_2024_e26863 crossref_primary_10_1515_biol_2022_0886 crossref_primary_10_1016_j_phymed_2024_156165 crossref_primary_10_1007_s10735_024_10252_y |
Cites_doi | 10.1016/j.bbadis.2017.03.006 10.1016/j.dsx.2017.12.029 10.1016/j.bcp.2008.06.020 10.1142/S0192415X1750063X 10.1016/j.jsps.2017.04.009 10.2147/DDDT.S152489 10.1111/fcp.12232 10.3892/ijmm.2016.2555 10.2337/dci15-0012 10.3892/etm.2016.3629 10.1155/2017/8095926 10.2147/DDDT.S166525 10.2147/DDDT.S171286 10.1016/S0140-6736(17)30058-2 10.1159/000486166 10.1016/j.freeradbiomed.2018.02.022 10.1016/j.ijcard.2018.09.023 10.4314/ajtcam.v11i4.1 10.1016/j.fct.2018.05.029 10.1186/s12933-017-0604-9 10.1016/j.biopha.2018.08.013 10.3892/etm.2016.3194 10.1038/aps.2016.175 10.1186/s12906-017-1930-x 10.3389/fphys.2018.00015 10.1177/0300060518778711 10.1159/000464122 10.2337/db09-9028 10.3109/0886022X.2013.867798 10.1038/cdd.2017.61 10.1001/jama.2014.15298 |
ContentType | Journal Article |
Copyright | The Author(s) 2021 The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 2019 SAGE Publications |
Copyright_xml | – notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 2019 SAGE Publications |
DBID | AFRWT AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.1177/0300060519841165 |
DatabaseName | Sage Journals GOLD Open Access 2024 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: AFRWT name: Sage Journals GOLD Open Access 2024 url: http://journals.sagepub.com/ sourceTypes: Publisher – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1473-2300 |
ExternalDocumentID | oai_doaj_org_article_932e40de86b44c28bd2df4f98c558471 PMC8166410 33706619 10_1177_0300060519841165 10.1177_0300060519841165 |
Genre | Journal Article |
GroupedDBID | --- .55 .GJ 01A 0R~ 29K 2WC 44B 53G 54M 5GY 5RE 5VS 7X7 8FI 8FJ AABQO AACKU AAFWJ AAGGD AAJIQ AAJOX AAJPV AAJQC AANSI AAPEO AAQQG AAQXH AASGM AAXOT AAYTG AAZBJ ABAFQ ABAWP ABDWY ABHKI ABJNI ABNCE ABPGX ABQKF ABQXT ABUWG ABVFX ABXGC ABYTW ACARO ACFMA ACFYK ACGBL ACGFS ACLHI ACROE ADBBV ADEIA ADMPF ADOGD ADQSQ ADTBJ ADUKL AECVZ AEFTW AENEX AERKM AEUHG AEWDL AEXFG AFCOW AFKBI AFKRA AFKRG AFPKN AFRWT AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AUTPY AYAKG BAWUL BCNDV BDDNI BENPR BPHCQ BSEHC BVXVI CBRKF CCPQU CORYS CQQTX CUTAK D-I DC. DF. DIK E3Z EBD EBS EF0 EJD EMOBN F5P FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HMCUK HYE J8X K.F KQ8 L7B MK0 O9- P2P PHGZM PHGZT PIMPY PQQKQ Q1R ROL RPM S01 SAUOL SCDPB SCNPE SFC SV3 TR2 TUS UKHRP X7M ZE2 ZGI AAYXX ACHEB CITATION OVT CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c528t-faf87a09fd63f1969314685b72e682a02812a825f20394d9bb8a06c50d53e8c93 |
IEDL.DBID | AFRWT |
ISSN | 0300-0605 1473-2300 |
IngestDate | Wed Aug 27 01:30:50 EDT 2025 Thu Aug 21 14:09:04 EDT 2025 Fri Jul 11 06:10:50 EDT 2025 Fri Jul 25 10:56:50 EDT 2025 Thu Apr 03 06:53:05 EDT 2025 Tue Jul 01 05:19:39 EDT 2025 Thu Apr 24 22:50:21 EDT 2025 Tue Jun 17 22:29:50 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | blood glucose rat model liver function protection diabetes mellitus Astragaloside IV blood lipids oxidative stress |
Language | English |
License | Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c528t-faf87a09fd63f1969314685b72e682a02812a825f20394d9bb8a06c50d53e8c93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-5945-4731 |
OpenAccessLink | https://journals.sagepub.com/doi/full/10.1177/0300060519841165?utm_source=summon&utm_medium=discovery-provider |
PMID | 33706619 |
PQID | 2507474384 |
PQPubID | 4451107 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_932e40de86b44c28bd2df4f98c558471 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8166410 proquest_miscellaneous_2501268845 proquest_journals_2507474384 pubmed_primary_33706619 crossref_citationtrail_10_1177_0300060519841165 crossref_primary_10_1177_0300060519841165 sage_journals_10_1177_0300060519841165 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-03-01 |
PublicationDateYYYYMMDD | 2021-03-01 |
PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | London, England |
PublicationPlace_xml | – name: London, England – name: England – name: London – name: Sage UK: London, England |
PublicationTitle | Journal of international medical research |
PublicationTitleAlternate | J Int Med Res |
PublicationYear | 2021 |
Publisher | SAGE Publications Sage Publications Ltd SAGE Publishing |
Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd – name: SAGE Publishing |
References | Chen, Gui, Chen 2008; 76 Li, Hou, Xu 2017; 31 Wang, Shao, Xu 2014; 36 Du, Zhang, Li 2018; 9 El Husseny, Mamdouh, Shaban 2017; 2017 Yu, Pan, Dong 2017; 1863 Wang, Chen, Yu 2018; 279 Zhou, Zhou, Wei 2017; 38 Qiao, Fan, Tang 2017; 11 Du, Xu, Gao 2018; 12 Inzucchi, Lipska, Mayo 2014; 312 Zhu, Zheng, Chen 2016; 37 Karam, Chavez-Moreno, Koh 2017; 16 Cai, Liu, Bian 2016; 12 Wang, Gan, Li 2017; 24 Defronzo 2009; 58 Khaki, Khaki, Hajhosseini 2014; 11 Wang, Li, Xiang 2017; 41 Miao, Liu, Wang 2017; 25 Tuhin, Begum, Rahman 2017; 17 Lee, Ma, Moulik 2018; 119 Qi, Gao, Hou 2017; 45 Chen, Wang, Wei 2016; 11 Song, Han, Sun 2018; 46 Robson, Kundur, Singh 2018; 12 Chatterjee, Khunti, Davies 2017; 389 Fox, Golden, Anderson 2015; 38 Gadelkarim, Abushouk, Ghanem 2018; 107 Li, Ding, Wu 2017; 44 Lei, Zhang, Li 2018; 12 Ghosh, Chowdhury, Sarkar 2018; 118 Mu, Zhang, Fan 2017; 25 bibr3-0300060519841165 bibr25-0300060519841165 bibr16-0300060519841165 bibr12-0300060519841165 bibr8-0300060519841165 bibr29-0300060519841165 bibr11-0300060519841165 bibr24-0300060519841165 bibr2-0300060519841165 bibr20-0300060519841165 bibr9-0300060519841165 bibr10-0300060519841165 bibr28-0300060519841165 bibr15-0300060519841165 Mu YP (bibr30-0300060519841165) 2017; 25 bibr1-0300060519841165 bibr23-0300060519841165 bibr32-0300060519841165 bibr19-0300060519841165 bibr5-0300060519841165 bibr27-0300060519841165 bibr14-0300060519841165 bibr6-0300060519841165 bibr31-0300060519841165 bibr18-0300060519841165 bibr22-0300060519841165 bibr21-0300060519841165 bibr26-0300060519841165 bibr4-0300060519841165 bibr7-0300060519841165 bibr13-0300060519841165 bibr17-0300060519841165 |
References_xml | – volume: 44 start-page: 2422 year: 2017 end-page: 2438 article-title: Astragaloside IV prevents cardiac remodeling in the apolipoprotein E-deficient mice by regulating cardiac homeostasis and oxidative stress. publication-title: Cell Physiol Biochem – volume: 107 start-page: 625 year: 2018 end-page: 633 article-title: Adipose-derived stem cells: effectiveness and advances in delivery in diabetic wound healing. publication-title: Biomed Pharmacother – volume: 24 start-page: 1111 year: 2017 end-page: 1120 article-title: Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. publication-title: Cell Death Differ – volume: 11 start-page: 2561 year: 2016 end-page: 2566 article-title: Effects of astragalosides from Radix Astragali on high glucose-induced proliferation and extracellular matrix accumulation in glomerular mesangial cells. publication-title: Exp Ther Med – volume: 41 start-page: 1156 year: 2017 end-page: 1166 article-title: Astragaloside alleviates hepatic fibrosis function via PAR2 signaling pathway in diabetic rats. publication-title: Cell Physiol Biochem – volume: 12 start-page: 455 year: 2018 end-page: 462 article-title: Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of cardiovascular disease risk. publication-title: Diabetes Metab Syndr – volume: 45 start-page: 1157 year: 2017 end-page: 1167 article-title: Anti-inflammatory and immunostimulatory activities of astragalosides. publication-title: Am J Chin Med – volume: 12 start-page: 2785 year: 2018 end-page: 2793 article-title: Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. publication-title: Drug Des Devel Ther – volume: 11 start-page: 3567 year: 2017 end-page: 3577 article-title: Astragaloside IV protects rat retinal capillary endothelial cells against high glucose-induced oxidative injury. publication-title: Drug Des Devel Ther – volume: 389 start-page: 2239 year: 2017 end-page: 2251 article-title: Type 2 diabetes. publication-title: Lancet – volume: 12 start-page: 2702 year: 2016 end-page: 2708 article-title: Astragaloside IV ameliorates necrotizing enterocolitis by attenuating oxidative stress and suppressing inflammation via the vitamin D3-upregulated protein 1/NF-kappaB signaling pathway. publication-title: Exp Ther Med – volume: 279 start-page: 147 year: 2018 article-title: Circular RNA DLGAP4 ameliorates cardiomyocyte apoptosis through regulating BCL2 via targeting miR-143 in myocardial ischemia-reperfusion injury publication-title: Int J Cardiol – volume: 11 start-page: 1 year: 2014 end-page: 8 article-title: The anti-oxidant effects of ginger and cinnamon on spermatogenesis dysfunction of diabetes rats. publication-title: Afr J Tradit Complement Altern Med – volume: 58 start-page: 773 year: 2009 end-page: 795 article-title: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. publication-title: Diabetes – volume: 2017 start-page: 8095926 year: 2017 article-title: Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. publication-title: J Diabetes Res – volume: 9 start-page: 15 year: 2018 article-title: Astragaloside IV inhibits adipose lipolysis and reduces hepatic glucose production via Akt dependent PDE3B expression in HFD-fed mice publication-title: Front Physiol – volume: 17 start-page: 423 year: 2017 article-title: Wound healing effect of Euphorbia hirta linn. (Euphorbiaceae) in alloxan induced diabetic rats publication-title: BMC Complement Altern Med – volume: 37 start-page: 1697 year: 2016 end-page: 1705 article-title: Astragaloside IV facilitates glucose transport in C2C12 myotubes through the IRS1/AKT pathway and suppresses the palmitate-induced activation of the IKK/IkappaBalpha pathway. publication-title: Int J Mol Med – volume: 25 start-page: 477 year: 2017 end-page: 481 article-title: The effect of different proportions of astragaloside and curcumin on DM model of mice. publication-title: Saudi Pharm J – volume: 25 start-page: 575 year: 2017 end-page: 582 article-title: [Mechanism of astragaloside prevents cholestatic liver fibrosis through inhibition of Notch signaling activation]. publication-title: Zhonghua Gan Zang Bing Za Zhi – volume: 36 start-page: 400 year: 2014 end-page: 406 article-title: Astragaloside IV inhibits high glucose-induced cell apoptosis through HGF activation in cultured human tubular epithelial cells. publication-title: Ren Fail – volume: 31 start-page: 17 year: 2017 end-page: 36 article-title: Research review on the pharmacological effects of astragaloside IV. publication-title: Fundam Clin Pharmacol – volume: 76 start-page: 796 year: 2008 end-page: 804 article-title: Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition. publication-title: Biochem Pharmacol – volume: 16 start-page: 120 year: 2017 article-title: Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes publication-title: Cardiovasc Diabetol – volume: 118 start-page: 272 year: 2018 end-page: 286 article-title: Ameliorative role of ferulic acid against diabetes associated oxidative stress induced spleen damage. publication-title: Food Chem Toxicol – volume: 119 start-page: 69 year: 2018 end-page: 74 article-title: Untimely oxidative stress in beta-cells leads to diabetes – role of circadian clock in beta-cell function. publication-title: Free Radic Biol Med – volume: 38 start-page: 1777 year: 2015 end-page: 1803 article-title: Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. publication-title: Diabetes Care – volume: 312 start-page: 2668 year: 2014 end-page: 2675 article-title: Metformin in patients with type 2 diabetes and kidney disease: a systematic review. publication-title: JAMA – volume: 46 start-page: 2883 year: 2018 end-page: 2897 article-title: Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. publication-title: J Int Med Res – volume: 1863 start-page: 1195 year: 2017 end-page: 1203 article-title: Astragaloside IV attenuates lead acetate-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway in vitro. publication-title: Biochim Biophys Acta Mol Basis Dis – volume: 38 start-page: 998 year: 2017 end-page: 1008 article-title: Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation. publication-title: Acta Pharmacol Sin – volume: 12 start-page: 3517 year: 2018 end-page: 3524 article-title: Combination of ginsenoside Rg1 and astragaloside IV reduces oxidative stress and inhibits TGF-beta1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy. publication-title: Drug Des Devel Ther – ident: bibr28-0300060519841165 doi: 10.1016/j.bbadis.2017.03.006 – ident: bibr7-0300060519841165 doi: 10.1016/j.dsx.2017.12.029 – ident: bibr19-0300060519841165 doi: 10.1016/j.bcp.2008.06.020 – ident: bibr13-0300060519841165 doi: 10.1142/S0192415X1750063X – ident: bibr21-0300060519841165 doi: 10.1016/j.jsps.2017.04.009 – ident: bibr24-0300060519841165 doi: 10.2147/DDDT.S152489 – ident: bibr22-0300060519841165 doi: 10.1111/fcp.12232 – ident: bibr18-0300060519841165 doi: 10.3892/ijmm.2016.2555 – ident: bibr3-0300060519841165 doi: 10.2337/dci15-0012 – ident: bibr25-0300060519841165 doi: 10.3892/etm.2016.3629 – ident: bibr11-0300060519841165 doi: 10.1155/2017/8095926 – ident: bibr16-0300060519841165 doi: 10.2147/DDDT.S166525 – ident: bibr26-0300060519841165 doi: 10.2147/DDDT.S171286 – ident: bibr2-0300060519841165 doi: 10.1016/S0140-6736(17)30058-2 – ident: bibr27-0300060519841165 doi: 10.1159/000486166 – ident: bibr6-0300060519841165 doi: 10.1016/j.freeradbiomed.2018.02.022 – ident: bibr1-0300060519841165 doi: 10.1016/j.ijcard.2018.09.023 – ident: bibr4-0300060519841165 doi: 10.4314/ajtcam.v11i4.1 – ident: bibr5-0300060519841165 doi: 10.1016/j.fct.2018.05.029 – ident: bibr8-0300060519841165 doi: 10.1186/s12933-017-0604-9 – ident: bibr9-0300060519841165 doi: 10.1016/j.biopha.2018.08.013 – ident: bibr14-0300060519841165 doi: 10.3892/etm.2016.3194 – ident: bibr31-0300060519841165 doi: 10.1038/aps.2016.175 – ident: bibr10-0300060519841165 doi: 10.1186/s12906-017-1930-x – ident: bibr17-0300060519841165 doi: 10.3389/fphys.2018.00015 – ident: bibr20-0300060519841165 doi: 10.1177/0300060518778711 – volume: 25 start-page: 575 year: 2017 ident: bibr30-0300060519841165 publication-title: Zhonghua Gan Zang Bing Za Zhi – ident: bibr32-0300060519841165 doi: 10.1159/000464122 – ident: bibr29-0300060519841165 doi: 10.2337/db09-9028 – ident: bibr15-0300060519841165 doi: 10.3109/0886022X.2013.867798 – ident: bibr23-0300060519841165 doi: 10.1038/cdd.2017.61 – ident: bibr12-0300060519841165 doi: 10.1001/jama.2014.15298 |
SSID | ssj0042652 |
Score | 2.3185117 |
Snippet | Objectives
To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.
Methods
Fifty diabetic rats were... To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Fifty diabetic rats were randomly placed... Objectives To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats. Methods Fifty diabetic rats were... To investigate the effects of astragaloside IV on blood glucose, blood lipids, and liver function in diabetic rats.OBJECTIVESTo investigate the effects of... |
SourceID | doaj pubmedcentral proquest pubmed crossref sage |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 300060519841165 |
SubjectTerms | Animals Antioxidants - metabolism Blood Glucose - metabolism Diabetes Diabetes Mellitus, Experimental - drug therapy Glucose Lipids Liver Liver - metabolism Oxidative Stress Pre-Clinical Research Report Rats Rodents Saponins Triterpenes |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KTrmUvusmLSqUhcKatSXZlo9tSEgLLTlsSm5GT2oI3pDdHAL98Z2RH5tNX5deJdkM0oznG834G4B32sjAS6VTIiJMpSWbK32e5kFUqEJOm5gu-PK1PD2Xny-KizutvqgmrKcH7jdugfjCy8x5VRopLVfGcRdkqJUtKMMXAx_0eWMw1X-D0e0UfJuUXKAmE_EIohUliW9mxwlFrv7fAcxf6yTvFHtF_3PyCB4OwJF96AV-DA989wRmZz3z9O2cLbc_Uq3nbMbOtpzUt0_hx3IsKGd088o03XCgc1hRt0726Ru7JgpX71gsZGdDIfsch2Or-mnisr1qHb5fd44NFA-eRtEgGLlIOmbWdqy_0m0tQwVbP4Pzk-Pl0Wk6NF5IbcHVJg06qEpndXClCMSfI-gHrcJU3JeKa4QkOdcYWgaeiVq62hils9IWmSuEV7YWz2GvW3X-JTDubF0h5lEGAy9XlxoRjFbKOselk0ElsBhPorEDKzk1x7hs8pGI_N7ZJfB-euKqZ-T4y9qPdLjTOuLSjgOoYc2gYc2_NCyBw1E1msHA1w0iRwzEpFAygbfTNJom5Vt051c3cU2OdqAkyvGi16RJEiEqBHt5nUC1o2M7ou7OdO33SP9NmV6ZZwnMSBu3Iv1pE179j004gH1O1Tyx-u4Q9jbXN_41wrGNeRMt7yf2LC4x priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF-0vvgiWr-itawgB8KFSzabZPMkWlqqoPThKvcW9lMDJTnvrg8F_3hnNpvE86Ovs5swZGYyszOzvyHkjVTcsULIGIEIY67R5gqbxqnLSlAhI5UvF3z-Upxf8k-rfBUSbtvQVjn8E_2P2nQac-QLcNUQ-fJM8HfrHzFOjcLqahihcZfcQ-gy1OpyNR64wPnkoYqAw1WSfCpTLpCGJDhzc0Sg2XNLHr3_XyHn352Tv7V_eY909pA8CKEkfd_L_hG5Y9tDMrvosahv5nQ5Xa3azumMXkwo1TePyc_l0GJOMRdLJeY8wF10OL-TfvxKNwjqag31re00tLbPgeyH148LV826MfB-2RoaQB8sUsFEKDpNFDxtWtoneRtNQeW2T8jl2eny5DwOoxhinTOxi510opRJ5UyROUTUyfDKVq5KZgvBJAQpKZNw2HQsySpuKqWETAqdJybPrNBV9pQctF1rnxPKjK5KiIKEgqOYqQoJMY0UQhvDuOFORGQxSKLWAaccx2Vc1ekATf6H7CLydnxi3WN03LL3Awp33Ifo2p7Qbb7VwVhriGktT4wVheJcM6EMM467Sugcq8ppRI4G1aiDyW_rSUEj8npcBmPFCoxsbXft96RgGYIDH896TRo5ybISwr-0iki5p2N7rO6vtM13DwiOtV-eJhGZoTZOLP3vI7y4nf-X5D7Dzh3faXdEDnaba_sKQq-dOvb29QuSPiep priority: 102 providerName: ProQuest |
Title | Treatment with astragaloside IV reduced blood glucose, regulated blood lipids, and protected liver function in diabetic rats |
URI | https://journals.sagepub.com/doi/full/10.1177/0300060519841165 https://www.ncbi.nlm.nih.gov/pubmed/33706619 https://www.proquest.com/docview/2507474384 https://www.proquest.com/docview/2501268845 https://pubmed.ncbi.nlm.nih.gov/PMC8166410 https://doaj.org/article/932e40de86b44c28bd2df4f98c558471 |
Volume | 49 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED_a9GUvY9_z2gUNRmAQL7Ys2_LTaEdCN1gJJd3yZmRJ3gKtU_LxEOgfvzvZTpZ1G3tJQFLiQ7qzfro7_Q7grSpEyROpfCIi9IUmm0ts6IdllKIKGVW4cMGXi-T8SnyextMDqNq7MM0MLt9TWhVK5F7WZN3kjR40QcYBaiYRiSD6kIL4Yz6sVzd57e1ui2pQC4Wn1zcU2daUD7nx29tth3DE0yTmHTg6HV1-m7Tvbtyu4ibuQOVYgngX2Lz3zL2NzPH9_wmk3s-1_CVhzO1ho0fwsAGf7LTWlsdwYKsn0BvX7NWbPpvsLmMt-6zHxjte681TuJu0SemMvLdMkZcEN5g5Vfxkn76yBdHAWsNcMjxrkuH72OzK3W87rme3M4P_ryrDGpoIS604d4y2WVIVNqtY7RaeaYZKunwGV6Ph5OO53xRv8HXM5covVSlTFWSlSaKSOHgiuuQVFym3ieQKYU3IFR5PSx5EmTBZUUgVJDoOTBxZqbPoOXSqeWVfAuNGZyniJlng4c1kiUIUpKTUxnBhRCk9GLQrkeuG2ZwKbFznYUtm_tvaefBu-4vbmtXjH2PPaHG344iP2zXMF9_zxrxzRMFWBMbKpBBCc1kYbkpRZlLHFIcOPThpVSNvVTxH9ImHORFJ4cGbbTeaN8VsVGXnazcmRFuSAuV4UWvSVpIoShEwhpkH6Z6O7Ym631PNfjgKcYoWizDwoEfauBPpb5Pw6n8HHsMDTlk_LkvvBDqrxdq-Rti2KrpwmE7TbmNx-H02vBhfdp0TBD-Ho-An-Xs_Cw |
linkProvider | SAGE Publications |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jj9MwFLZGwwEuiJ3AAEaCSkiNmjhO4hwQYhu1zKI5dFBvwfEyRBolpe0IVeI38Rt5z1lKWeY2V9upnvp2v-fvEfJCFtyyREgfgQh9rlDnEhP6oY1SECEtC1cuODpOxqf80yye7ZCf3VsYbKvsbKIz1LpWeEc-AlcNkS-PBH8z_-bj1CisrnYjNBqxODDr75CyLV9PPgB_XzK2_3H6fuy3UwV8FTOx8q20IpVBZnUSWQSHifD1UVykzCSCSfC3IZOQN1kWRBnXWVEIGSQqDnQcGaEQfAlM_jVwvAEme-msT_DA2cVt1QKHuQTxpiw6wjVcghyfI-LNlht00wL-FeL-3an5W7uZ84D7t8jNNnSlbxtZu012THWHDE4a7Ov1kE43T7mWQzqgJxtU7PVd8mPatbRTvPulEu9YwD3VOC-UTj7TBYLIGk1dKz1tW-mHsHyGE8b6jfNyXmr4fVlp2oJMGFwFlaTopFHQaFnR5lK5VBREfHmPnF4Jk-6T3aquzENCmVZZClGXKCD101kiIYaSQiitGdfcCo-MOk7kqsVFx_Ec53nYQaH_wTuPvOq_mDeYIJecfYfM7c8hmrdbqBdneWsccoihDQ-0EUnBuWKi0ExbbjOhYqxihx7Z60Qjb03MMt8ohEee99tgHLDiIytTX7gzIWii4EDHg0aSekqiKIVwM8w8km7J2Bap2ztV-dUBkGOtmYeBRwYojRuS_vcnPLqc_mfk-nh6dJgfTo4PHpMbDLuGXJffHtldLS7MEwj7VsVTp2uUfLlq5f4FMPhi8A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED9BJyFeEN8LDDASqoTU0MRxEudxfFQbH1OFOthb5MQ2RJrSqu0eJvHHc-c4LWWAeLWd6JS7y_3sO_8O4IWqhOWZVCEREYaiJp_LTBzGNsnRhLSqXLrg00l2dCren6VnvjaH7sL4L7h6RWVVKJH7WZN3L7Qd-xzjGA2TeEQQfEhB9DHXYU8I3OMNYO9w8vnrrP8VY_RJfRqBuqtE6TZPeeUdO3HJ0ff_CXNeLZ38pf7LhaTJbbjlsSQ77JR_B66Z9i4Mpx0Z9eWIzbZ3q1YjNmTTLU315T34MetrzBkdxjJFhx4YL-bUwJMdf2FLYnU1mrnaduZr20c47LrXbybOm0Wj8f2q1cyzPhgaRR9hFDVJ86xpWXfK29QMbW51H04n72ZvjkLfiyGsUy7XoVVW5ioqrM4SS5Q6Cd3ZSqucm0xyhSgl5gp3m5ZHSSF0UVVSRVmdRjpNjKyL5AEM2nlr9oFxXRc5wiBZ4V5MF5lCUKOkrLXmQgsrAxj3mihrT1RO_TLOy7jnJv9NdwG83Dyx6Eg6_rH2NSl3s47otd3AfPmt9N5aIqg1ItJGZpUQNZeV5toKW8g6pbRyHMBBbxplb7Elgkncm4lEigCeb6bRWykFo1ozv3BrYnQNKVCOh50lbSRJkhzxX1wEkO_Y2I6ouzNt890xglPyV8RRAEOyxq1If_sIj_534TO4MX07KT8en3x4DDc51fO4-rsDGKyXF-YJArJ19dS73U-dzCky |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+with+astragaloside+IV+reduced+blood+glucose%2C+regulated+blood+lipids%2C+and+protected+liver+function+in+diabetic+rats&rft.jtitle=Journal+of+international+medical+research&rft.au=Han%2C+Dong&rft.date=2021-03-01&rft.pub=SAGE+Publications&rft.issn=0300-0605&rft.eissn=1473-2300&rft.volume=49&rft.issue=3&rft_id=info:doi/10.1177%2F0300060519841165&rft.externalDocID=10.1177_0300060519841165 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0605&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0605&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0605&client=summon |